TG Therapeutics Inc (TGTX)

NASDAQ
8.31
-0.06(-0.72%)
After Hours
8.11
-0.20(-2.41%)
- Real-time Data
  • Volume:
    1,852,725
  • Day's Range:
    8.02 - 8.52
  • 52 wk Range:
    3.48 - 20.69

TGTX Overview

Prev. Close
8.37
Day's Range
8.02-8.52
Revenue
5.03M
Open
8.27
52 wk Range
3.48-20.69
EPS
-1.78
Volume
1,852,725
Market Cap
1.11B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
2,644,182
P/E Ratio
-4.71
Beta
2.22
1-Year Change
-48.65%
Shares Outstanding
133,915,138
Next Earnings Date
Mar 09, 2023
What is your sentiment on TG?
or
Market is currently closed. Voting is open during market hours.

TG Therapeutics Inc News

TG Therapeutics Inc Analysis

TG Therapeutics Inc Company Profile

TG Therapeutics Inc Company Profile

Employees
173

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.

Read More

Analyst Price Target

Average17.56 (+111.26% Upside)
High40.00
Low4.00
Price8.31
No. of Analysts9
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellNeutralBuySell
Technical IndicatorsStrong SellStrong SellBuyStrong BuyStrong Sell
SummaryStrong SellStrong SellNeutralStrong BuyStrong Sell
  • wow, very big POS
    1
    • starting to wonder, who the real longs are on ST.
      0
      • Trying to get the 2020 club members, to post on this forum …..
        0
        • ivosplash, ian ….. you there ?
          0
          • ern1in … that's me !
            0
            • bigarena ….. you out there ?
              0
              • lets get board ….. rockin !
                0
                • I welcomed the 60% hair cut. Added a lot more shares, and lowered my average. SP, was dragged down on bs. Add all you can, at these ridiculously low levels. I don't day trade. I INVEST, IN TGTX !
                  0
                  • Great just great!!
                    0
                    • Just too high of a valuation. Shorted at 13.85
                      1
                      • You are gonna pay my friend.
                        0
                      • Hope you held onto that short. Well done!!
                        0